805319-85-1

Basic information

• Product Name: 2-BROMO-5-CHLORO-8-METHYL-8H-IMIDAZO[4,5-D]THIAZOLO[5,4-B]PYRIDINE
• Synonyms: 2-BROMO-5-CHLORO-8-METHYL-8H-IMIDAZO[4,5-D]THIAZOLO[5,4-B]PYRIDINE
• CAS NO: 805319-85-1
• Molecular Formula: C₈H₄BrClN₄S
• Molecular Weight: 303.571
• Mol File: 805319-85-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BROMO-5-CHLORO-8-METHYL-8H-IMIDAZO[4,5-D]THIAZOLO[5,4-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-5-CHLORO-8-METHYL-8H-IMIDAZO[4,5-D]THIAZOLO[5,4-B]PYRIDINE(805319-85-1)
• EPA Substance Registry System: 2-BROMO-5-CHLORO-8-METHYL-8H-IMIDAZO[4,5-D]THIAZOLO[5,4-B]PYRIDINE(805319-85-1)

Safety Data

• Hazardous Substances Data: 805319-85-1(Hazardous Substances Data)

Upstream product

• 805319-88-4 7-chloro-4-methyl-2-amino-4H-imidazo[4,5-d]thiazolo[5,4-b]-pyridine 
• 887254-60-6 1-(7-chloro-4-methyl-4H-imidazo[4,5-d]thiazolo[4,5-b]pyridin-2-yl)hydrazine 

Downstream Products

• 805319-89-5 1-[4-[8-methyl-5-chloro-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-2-yl]phenyl]-ethanone 
• 887251-57-2 N-[(S)1-[3-[7-chloro-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-2-yl]phenyl]ethyl]acetamide 
• 1134816-47-9 N-[[3-[8-methyl-5-chloro-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine-2-yl]phenyl]methyl]-tert-butyl carbamate 
• 805321-17-9 8-methyl-2-(4-fluorophenyl)-5-chloro-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine 
• 887254-73-1 alpha,alpha-dimethyl-3-(7-chloro-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-2-yl)-benzeneacetic acid ethyl ester 
• 887254-68-4 N-[(R,S)1-[3-[7-chloro-8-methyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-2-yl]phenyl]ethyl]acetamide 

Relevant articles and documents

Novel tricyclic inhibitors of 1κB kinase

The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of IκB kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

IMIDAZO-FUSED OXAZOLO[4,5-B]PYRIDINE AND IMIDAZO-FUSED THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I),[chemical structure] wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.